Structure Therapeutics (NASDAQ:GPCR) Cut to “Sell” at Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other analysts have also recently weighed in on GPCR. Morgan Stanley increased their price objective on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. JPMorgan Chase & Co. raised their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Guggenheim boosted their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $104.45.

Structure Therapeutics Trading Up 1.5%

Shares of NASDAQ GPCR opened at $88.45 on Friday. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90. The company has a market cap of $5.37 billion, a price-to-earnings ratio of -72.50 and a beta of -2.05. The stock’s 50 day simple moving average is $66.22 and its 200 day simple moving average is $38.93.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. CWM LLC grew its position in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after buying an additional 413 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after buying an additional 444 shares in the last quarter. Assetmark Inc. raised its position in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.